Abstract
The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis. These poor clinical characteristics stem from a poor understanding of the molecular abnormalities that drive disease pathogenesis. MicroRNAs (miRNAs) have recently been described to play wide-ranging roles in normal and malignant hematopoiesis, but very few miRNAs have been shown to be consistently dysregulated in MDS. Even fewer candidate disease miRNAs have undergone functional validation, and the clinical relevance of these miRNAs remains to be determined. Despite the fact that MDS has been shown to be a disease initiated in hematopoietic stem cells (HSC), most existing studies examining miRNA expression in MDS have used unfractionated or only partially purified bone marrow (BM) cell populations, likely explaining in part the limited insight that provided by these studies. A more robust characterization of purified disease -initiating cell populations followed by rigorous functional validation using in vivo disease models will be vital to identifying dysregulated miRNAs of functional significance in MDS. Such studies promise to provide key insights into disease pathogenesis and potentially open new avenues towards the development of therapies targeting miRNAs themselves or the pathways that they regulate.
Keywords: Bone marrow failure, hematopoietic stem cell, malignant hematopoiesis, microRNA, myelodysplasia, the myelodysplastic syndromes.
MicroRNA
Title:MicroRNA Dysregulation in the Myelodysplastic Syndromes
Volume: 2 Issue: 3
Author(s): Stephen S. Chung and Christopher Y. Park
Affiliation:
Keywords: Bone marrow failure, hematopoietic stem cell, malignant hematopoiesis, microRNA, myelodysplasia, the myelodysplastic syndromes.
Abstract: The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis. These poor clinical characteristics stem from a poor understanding of the molecular abnormalities that drive disease pathogenesis. MicroRNAs (miRNAs) have recently been described to play wide-ranging roles in normal and malignant hematopoiesis, but very few miRNAs have been shown to be consistently dysregulated in MDS. Even fewer candidate disease miRNAs have undergone functional validation, and the clinical relevance of these miRNAs remains to be determined. Despite the fact that MDS has been shown to be a disease initiated in hematopoietic stem cells (HSC), most existing studies examining miRNA expression in MDS have used unfractionated or only partially purified bone marrow (BM) cell populations, likely explaining in part the limited insight that provided by these studies. A more robust characterization of purified disease -initiating cell populations followed by rigorous functional validation using in vivo disease models will be vital to identifying dysregulated miRNAs of functional significance in MDS. Such studies promise to provide key insights into disease pathogenesis and potentially open new avenues towards the development of therapies targeting miRNAs themselves or the pathways that they regulate.
Export Options
About this article
Cite this article as:
Chung S. Stephen and Park Y. Christopher, MicroRNA Dysregulation in the Myelodysplastic Syndromes, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/2211536602666131126002621
DOI https://dx.doi.org/10.2174/2211536602666131126002621 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Benzocoumarins: Isolation, Synthesis, and Biological Activities
Mini-Reviews in Medicinal Chemistry Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Cationic Liposomes as In Vivo Delivery Vehicles
Current Medicinal Chemistry Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Nutritional Support in Cancer
Current Nutrition & Food Science The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Three-Dimensional Intravenous Digital Subtraction Angiography Using Flat Panel Detector System in Vascular Mapping of the External Carotid Artery: A Comparison with 3-Dimensional Computed Tomography Angiography
Current Medical Imaging Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
Current Pharmaceutical Biotechnology Chemical Aspects of Coumarin Compounds for the Prevention of Hepatocellular Carcinomas
Current Medicinal Chemistry - Anti-Cancer Agents Implementation of “Quality by Design (QbD)” Approach for the Development of 5-Fluorouracil Loaded Thermosensitive Hydrogel
Current Drug Delivery The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Cellular and Physiological Effects of Soy Flavonoids
Mini-Reviews in Medicinal Chemistry